Zhejiang Anglikang Pharmaceutical 昂利康
22 significant filings since 29 May 2026: 14 on share issue, 2 on guarantee or financial assistance and 1 on equity incentive, and 3 other kinds. The latest, on 23 Sep 2026: 关于第一期员工持股计划存续期展期的公告.
自 29 May 2026 起有 22 份重大公告：share issue 14 份、guarantee or financial assistance 2 份、equity incentive 1 份，另有 3 类。最新一份（23 Sep 2026）：关于第一期员工持股计划存续期展期的公告。
No broker reports from the last twelve months are held for this company. Brokers covered 1,060 of the 2,940 SZSE listings (36%) over the same period. 近十二个月无本公司研报；同期券商覆盖了 2,940 只 SZSE 证券中的 1,060 只（36%）。
No broker has changed its rating on this company in the reports held.
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。